{"id":"cytarabine-venetoclax-association","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Cytarabine inhibits DNA synthesis by acting as an antimetabolite, while venetoclax selectively binds to BCL-2, a protein that prevents apoptosis, thereby promoting cell death in cancer cells. The combination enhances the cytotoxic effect against leukemia cells.","oneSentence":"Cytarabine-Venetoclax Association works by combining cytarabine's DNA synthesis inhibition with venetoclax's selective inhibition of BCL-2 protein, leading to enhanced apoptosis in leukemia cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:09:39.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute Myeloid Leukemia (AML) in adults who are ineligible for intensive chemotherapy"}]},"trialDetails":[{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT04801797","phase":"PHASE2","title":"Venetoclax + Azacitidine vs. Induction Chemotherapy in AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-05-20","conditions":"Acute Myeloid Leukemia","enrollment":172},{"nctId":"NCT04968015","phase":"PHASE2","title":"Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2022-05-25","conditions":"Acute Myeloid Leukemia","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cytarabine-Venetoclax Association","genericName":"Cytarabine-Venetoclax Association","companyName":"French Innovative Leukemia Organisation","companyId":"french-innovative-leukemia-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytarabine-Venetoclax Association works by combining cytarabine's DNA synthesis inhibition with venetoclax's selective inhibition of BCL-2 protein, leading to enhanced apoptosis in leukemia cells. Used for Acute Myeloid Leukemia (AML) in adults who are ineligible for intensive chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}